Evolent Health, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jeffrey Garro from Stephens upgraded the rating on the stock to a Buy and gave it a $7.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jeffrey Garro has given his Buy rating due to a combination of factors that suggest Evolent Health is poised for growth. The company has shown resilience by surpassing third-quarter expectations, which indicates a stabilization in its performance despite previous market concerns. Additionally, the end of the government shutdown without subsidy extensions aligns with the company’s forecasts, further supporting its strategic planning.
Garro also highlights that Evolent Health’s current market sentiment is at a low, suggesting potential for improvement. The company’s fundamental position has strengthened compared to previous years, and it has a promising growth trajectory with new revenue opportunities. Even under conservative assumptions, there is potential for valuation upside, making the stock an attractive buy at this time.
In another report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $12.00 price target.